Cipla rises on receiving USFDA nod for Lopinavir, Ritonavir oral pellets

05 Jun 2015 Evaluate

Cipla is currently trading at Rs. 630.75, up by 1.00 points or 0.16% from its previous closing of Rs. 629.75 on the BSE.

The scrip opened at Rs. 630.20 and has touched a high and low of Rs. 637.00 and Rs. 625.80 respectively. So far 73,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 385.00 on 05-Jun-2014.

Last one week high and low of the scrip stood at Rs. 672.60 and Rs. 625.80 respectively. The current market cap of the company is Rs. 50,626.00 crore.

The promoters holding in the company stood at 36.80%, while Institutions and Non-Institutions held 35.18% and 25.83% respectively.

Cipla, a global pharmaceutical company, has received United States Food and Drug Administration (USFDA) approval for an innovative formulation - Lopinavir/ ritonavir (LPV/r) 40mg/ 10 mg oral pellets - for paediatric specific treatment for infants.

Cipla has long recognized the lack of access to life saving child-friendly formulations for the treatment of HIV, which prompted it to develop an innovative formulation of LPV/r oral pellets. The pellets are to be sprinkled on sweetened porridge for infants and administered to them. The pellets are produced by melt-extrusion technology and are enclosed in capsules.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.



Cipla Share Price

1495.00 3.60 (0.24%)
31-Dec-2025 09:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.90
Dr. Reddys Lab 1262.60
Cipla 1495.00
Zydus Lifesciences 908.95
Lupin 2083.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×